ZA8.F ZYMEWORKS DL-00001
- Market cap
- EUR 1.81B
- P/E
- 55.8x
- P/B
- 8.41x
- ROE
- 43.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ZA8.F undervalued?
Graham numberThe Graham number of ZYMEWORKS DL-00001 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ZYMEWORKS DL-00001 fundamental analysis
No fundamental analysis for ZYMEWORKS DL-00001 yet.
ZYMEWORKS DL-00001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ZYMEWORKS DL-00001
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; an…
Full company profileZYMEWORKS DL-00001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ZYMEWORKS DL-00001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 26.7M | 412M | 76.0M | 76.3M | 106M | 351M |
| Operating Income | -216M | 130M | -138M | -120M | -92.5M | 118M |
| EBITDA | - | 142M | -121M | -109M | -81.4M | 139M |
| Net Income | -212M | 124M | -119M | -123M | -81.1M | 113M |
| EPS | -4.54 | 1.97 | -1.69 | -1.78 | -1.08 | 1.57 |
| Balance Sheet | ||||||
| Total Assets | 389M | 649M | 581M | 463M | 347M | 1.18B |
| Total Liabilities | 140M | 156M | 116M | 124M | 78.0M | 918M |
| Shareholders' Equity | 249M | 493M | 465M | 339M | 269M | 258M |
| Cash & Short-term Investments | 202M | 401M | 158M | 66.1M | 41.2M | 100M |
| Cash Flow | ||||||
| Operating Cash Flow | -192M | 144M | -118M | -110M | -33.0M | -136M |
| Capital Expenditure | 13.3M | 13.1M | 4.08M | 3.07M | 2.35M | 385K |
| Free Cash Flow | -206M | 131M | -122M | -113M | -35.4M | -136M |
| Ratios | ||||||
| ROE | -85.0% | 25.2% | -25.5% | -36.2% | -30.2% | 43.6% |
| ROA | -54.4% | 19.2% | -20.4% | -26.5% | -23.4% | 9.6% |
| Net Profit Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% | 32.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ZYMEWORKS DL-00001 dividends
ZYMEWORKS DL-00001 has not paid dividends in the last 5 fiscal years.
Who owns ZYMEWORKS DL-00001
- Insiders 1.37%
- Institutions 98.63%
- Public & others 0.00%
- Shares outstanding 69.0M
- Free float 64.0M
ZYMEWORKS DL-00001 company profile
- Company name
- ZYMEWORKS DL-00001
- Ticker
- ZA8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 279
- Fiscal year end
- December
- Address
- 108 Patriot Drive, Middletown, DE, United States, 19709
- Phone
- 302 274 8744
- Website
- zymeworks.com
About ZYMEWORKS DL-00001
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
ZYMEWORKS DL-00001 management
10- Mr. Kenneth H. Galbraith C.A.Chairman of the Board, CEO & President · born 1962
- Dr. Paul A. Moore Ph.D.Chief Scientific Officer · born 1967
- Mr. Scott Platshon B.S.Executive VP & Chief Business Officer · born 1991
- Ms. Kristin Stafford CPAExecutive VP & CFO · born 1982
- Mr. Mark HollywoodExecutive VP & COO · born 1969
- Mr. Stuart KnightExecutive VP & Chief Information Officer
- Mr. Paul R. SchneiderExecutive VP & General Counsel · born 1971
- Dr. Lindsey Foulkes B.Sc., Ph.D.Senior Vice President of Corporate Development & Strategy
- Ms. Laura O'ConnorSenior VP & Chief Human Resources Officer
- Ms. Bijal Desai M.B.A.Senior Vice President of Finance